**Supplemental Tables 3.** Incidence and Classification of Adverse Events in the Safety Set.

|  |  |  |  |
| --- | --- | --- | --- |
|  | NSAID group(n=125) | Steroid group(n=125) | *Intergroup p value\** |
| AE | 6(4.80),[6] | 6(4.80),[6] | 1.0000(C) |
| 95% CI1) | [1.78, 10.15] | [1.78, 10.15] |
| Eye disorders | 5(4.00),[5] | 5(4.00),[5] |  |
| Conjunctival hemorrhage | 1(0.80),[1] | 0(0.00),[0] |  |
| Conjunctivitis allergic | 1(0.80),[1] | 0(0.00),[0] |  |
| Cystoid macular edema | 0(0.00),[0] | 1(0.80),[1] |  |
| Dry eye | 1(0.80),[1] | 2(1.60),[2] |  |
| Eye inflammation | 1(0.80),[1] | 0(0.00),[0] |  |
| Lacrimation increased | 0(0.00),[0] | 1(0.80),[1] |  |
| Macular degeneration | 1(0.80),[1] | 1(0.80),[1] |  |
| Infections and infestations | 1(0.80),[1] | 1(0.80),[1] |  |
| Adenoviral conjunctivitis | 1(0.80),[1] | 1(0.80),[1] |  |
| ADR | 1(0.80),[1] | 1(0.80),[1] | 1.0000(F) |
| 95% CI | [0.02, 4.38] | [0.02, 4.38] |  |
| Eye disorders | 1(0.80),[1] | 1(0.80),[1] |  |
| Dry eye | 1(0.80),[1] | 1(0.80),[1] |  |
| Serious AE | 0(0.00),[0] | 0(0.00),[0] |  |
| 95% CI | [0.00, 2.91] | [0.00, 2.91] |
| Serious ADR | 0(0.00),[0] | 0(0.00),[0] |  |
| 95% CI | [0.00, 2.91] | [0.00, 2.91] |  |

ADR, adverse drug reaction; AE, adverse event, Clopper-Pearson Confidence Interval

number of subjects(percentage of subjects),[number as events]
\*Pearson’s chi-square test (C) or Fisher’s exact test (F)